The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Event outline

Event Outline

Diagnosis and treatment of cancer has seen a steep evolution of new treatment paradigms in the recent years. In this multi-stakeholder workshop organized by the Cancer Drug Development Forum, multidisciplinary experts will discuss key emerging treatment modalities – looking at these new developments from scientific, regulatory and practical perspectives. Novel modalities to be covered include: radiopharmaceuticals as a means to both diagnose and treat tumors; personalized vaccines as cancer immunotherapeutics; the next generation of targeted conjugates; and new approaches to tackle previously undruggable targets. In addition, cellular therapies like CAR-T cells, having become standard of care in several cancers, are still evolving, and we will cover lessons learned and the implications for new approaches on the horizon.

This multistakeholder workshop will give participants the opportunity to hear about the latest developments from hands-on experts in the field. The 1.5 day meeting consists of four plenary sessions. Panel discussions will enhance each session, always striving to involve the patient perspective, and the perspective of Regulatory Authorities. There will be time for discussion and networking, involving multiple stakeholders including industry, academics, regulatory agencies, HTAs, and, importantly, patient advocates. 

 

Learning outcomes / Meeting objective

From this interactive workshop, participants will achieve the following outcomes:

  • To understand the latest treatment paradigms in the diagnosis and treatment of cancer
  • To learn about regulatory principles, including practical aspects which help regulating new modalities
  • To look back at what can be learned from current cutting edge treatments already authorized, enabling a wider view of how to develop new paradigms in future

 

Target audience

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), the pharmaceutical industry, HTAs, and patient advocates.

 

Language

The main language of the workshop is English.

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70